Gubra is an ambitious and innovative biotech company striving for excellence at all levels. We insist on doing things efficiently – and often differently - to reach the results we aim for. Our vision is to become leaders in the fight for a more sustainable and healthier world. We do that by facilitating the discovery of new medicine, and by acting and inspiring others to fight against the ongoing climate and biodiversity crises. We have two primary areas of business: Preclinical contract research (CRO) services, and Proprietary early target and drug discovery programs. We are a biotech company delivering science to our partners and to our own research projects. We are active in the so-called pre-clinical space - before drugs are tested in humans - and generate our revenue by performing research for small and large pharma companies. Our focus is within the metabolic space (obesity, diabetes, NASH (Non-alcoholic steatohepatitis), and diabetic complications), where we specialize in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, stereology, imaging, NGS (next generation sequencing), bioinformatics and biomarker assays. We work with some of the most interesting and loyal partners and customers from across the world within big pharma, biotech, and academia. Through a constant focus on high quality, scientific excellence, speed, and solid teamwork we have established ourselves as a highly professional and competent partner in the market. People are our greatest asset, and our team consists of +200 employees all located in Hørsholm, Denmark. The mix of people from different cultures and educational backgrounds combined with our entrepreneurial mindset have greatly impacted our working environment, which is characterized by intensive drive, scientific curiosity, and teamwork – we join forces!